A Retrospective Comparison of TECAM and BEAM Conditioning Regimens Before Autologous Hematopoietic Stem Cell Transplant in Lymphoma Patients: Efficacy and Toxicity.

IF 0.7 4区医学 Q4 TRANSPLANTATION

Experimental and Clinical Transplantation Pub Date : 2025-04-01 Epub Date: 2018-06-28 DOI:10.6002/ect.2017.0274

Pusem Patir, Nur Soyer, Isabel Raika Durusoy, Fahri Sahin, Guray Saydam, Mahmut Tobu, Murat Tombuloglu, Filiz Vural

{"title":"A Retrospective Comparison of TECAM and BEAM Conditioning Regimens Before Autologous Hematopoietic Stem Cell Transplant in Lymphoma Patients: Efficacy and Toxicity.","authors":"Pusem Patir, Nur Soyer, Isabel Raika Durusoy, Fahri Sahin, Guray Saydam, Mahmut Tobu, Murat Tombuloglu, Filiz Vural","doi":"10.6002/ect.2017.0274","DOIUrl":null,"url":null,"abstract":"Objectives: The aim of our study was to evaluate the efficacy and toxicity of TECAM (thiotepa, etoposide, cyclophosphamide, cytarabine, and melphalan) and BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimens before autologous hematopoietic stem cell transplant in patients with lymphoma.Materials and methods: We retrospectively analyzed 108 relapsed/refractory lymphoma patients who had high-dose treatments followed by autologous hematopoietic stem cell transplant between October 2012 and February 2017.Results: At a median follow-up period of 16 months, the estimated 2-year progression-free survival rates for the TECAM and BEAM groups were 55.7% and 52.9%, respectively (P = .811). The estimated 2-year overall survival rate in the TECAM group (55.9%) was relatively inferior to that shown in the BEAM group (67%), but the differences were not significant (P = .238). No differences were observed for time to hematopoietic recovery and duration of hospitalization. Incidences of transplant-related infectious and noninfectious complications were similar for each conditioning regimen.Conclusions: Our experience shows that the TECAM regimen is an effective high-dose chemotherapy for lymphoma patients before autologous hematopoietic stem cell transplant.","PeriodicalId":50467,"journal":{"name":"Experimental and Clinical Transplantation","volume":" ","pages":"299-305"},"PeriodicalIF":0.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.6002/ect.2017.0274","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/6/28 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"TRANSPLANTATION","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The aim of our study was to evaluate the efficacy and toxicity of TECAM (thiotepa, etoposide, cyclophosphamide, cytarabine, and melphalan) and BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimens before autologous hematopoietic stem cell transplant in patients with lymphoma.

Materials and methods: We retrospectively analyzed 108 relapsed/refractory lymphoma patients who had high-dose treatments followed by autologous hematopoietic stem cell transplant between October 2012 and February 2017.

Results: At a median follow-up period of 16 months, the estimated 2-year progression-free survival rates for the TECAM and BEAM groups were 55.7% and 52.9%, respectively (P = .811). The estimated 2-year overall survival rate in the TECAM group (55.9%) was relatively inferior to that shown in the BEAM group (67%), but the differences were not significant (P = .238). No differences were observed for time to hematopoietic recovery and duration of hospitalization. Incidences of transplant-related infectious and noninfectious complications were similar for each conditioning regimen.

Conclusions: Our experience shows that the TECAM regimen is an effective high-dose chemotherapy for lymphoma patients before autologous hematopoietic stem cell transplant.

查看原文本刊更多论文

淋巴瘤患者自体造血干细胞移植前TECAM和BEAM治疗方案的回顾性比较：疗效与毒性。

研究目的我们的研究旨在评估淋巴瘤患者自体造血干细胞移植前TECAM（噻替帕、依托泊苷、环磷酰胺、阿糖胞苷和美法仑）和BEAM（卡莫司汀、依托泊苷、阿糖胞苷和美法仑）调理方案的疗效和毒性：我们对2012年10月至2017年2月期间接受高剂量治疗后进行自体造血干细胞移植的108例复发/难治性淋巴瘤患者进行了回顾性分析：中位随访期为16个月，TECAM组和BEAM组的估计2年无进展生存率分别为55.7%和52.9%（P = .811）。TECAM组的估计2年总生存率（55.9%）相对低于BEAM组（67%），但差异不显著（P = .238）。在造血功能恢复时间和住院时间方面没有观察到差异。每种调理方案的移植相关感染性和非感染性并发症发生率相似：我们的经验表明，TECAM方案是自体造血干细胞移植前对淋巴瘤患者有效的大剂量化疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Experimental and Clinical Transplantation 医学-移植

CiteScore

1.40

自引率

11.10%

发文量

258

审稿时长

6-12 weeks

期刊介绍： The scope of the journal includes the following: Surgical techniques, innovations, and novelties; Immunobiology and immunosuppression; Clinical results; Complications; Infection; Malignancies; Organ donation; Organ and tissue procurement and preservation; Sociological and ethical issues; Xenotransplantation.